Neil Gregory Almstead Sells 1,279 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Neil Gregory Almstead sold 1,279 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $76.95, for a total value of $98,419.05. Following the sale, the insider directly owned 117,103 shares in the company, valued at $9,011,075.85. The trade was a 1.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Neil Gregory Almstead also recently made the following trade(s):

• On Wednesday, January 7th, Neil Gregory Almstead sold 52 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total value of $4,028.96.
• On Wednesday, January 7th, Neil Gregory Almstead sold 1,026 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total value of $79,494.48.
• On Tuesday, January 6th, Neil Gregory Almstead sold 54 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $4,155.30.
• On Monday, November 24th, Neil Gregory Almstead sold 35,572 shares of PTC Therapeutics stock. The shares were sold at an average price of $80.18, for a total value of $2,852,162.96.
• On Tuesday, November 25th, Neil Gregory Almstead sold 71,928 shares of PTC Therapeutics stock. The stock was sold at an average price of $83.44, for a total value of $6,001,672.32.

PTC Therapeutics Stock Performance

Shares of PTCT stock opened at $77.53 on Friday. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50. The company’s 50 day moving average price is $76.61 and its two-hundred day moving average price is $62.72. The company has a market capitalization of $6.22 billion, a P/E ratio of 9.06 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The company had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. During the same quarter in the prior year, the company earned ($1.39) earnings per share. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. Analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Institutional Investors Weigh In On PTC Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Empowered Funds LLC acquired a new stake in shares of PTC Therapeutics in the 1st quarter valued at approximately $1,999,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in PTC Therapeutics by 11.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 178,755 shares of the biopharmaceutical company’s stock worth $9,109,000 after acquiring an additional 18,504 shares in the last quarter. Bayforest Capital Ltd bought a new stake in PTC Therapeutics during the first quarter worth $415,000. Intech Investment Management LLC lifted its stake in PTC Therapeutics by 62.8% in the first quarter. Intech Investment Management LLC now owns 39,307 shares of the biopharmaceutical company’s stock valued at $2,003,000 after acquiring an additional 15,167 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its stake in PTC Therapeutics by 6.1% in the first quarter. Acadian Asset Management LLC now owns 37,435 shares of the biopharmaceutical company’s stock valued at $1,904,000 after acquiring an additional 2,140 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on PTCT shares. Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, November 5th. Jefferies Financial Group upped their price target on PTC Therapeutics from $63.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Morgan Stanley reaffirmed an “overweight” rating and set a $90.00 price target on shares of PTC Therapeutics in a research note on Thursday. TD Cowen lifted their price objective on shares of PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, November 5th. Finally, Citigroup boosted their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $77.27.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent quarterly results showed an upside surprise (EPS and revenue beat), supporting valuation and reducing near-term execution risk. MarketBeat PTCT Summary
• Positive Sentiment: At least one independent researcher upgraded PTC from Hold to Buy (Wall Street Zen), and several firms have raised price targets in November — a bullish offset to otherwise muted analyst sentiment. Wall Street Zen Upgrade
• Neutral Sentiment: Analysts as a group still carry a consensus “Hold” rating on PTCT, indicating limited immediate upside from broker consensus alone. Analyst Consensus
• Neutral Sentiment: The company reported a routine inducement grant of 300 RSUs for a new non-executive hire under Nasdaq rules — small dilution and not material to fundamentals. PR Newswire
• Negative Sentiment: A director executed a large sale totaling $916,200, a notable insider disposition that can weigh on sentiment. Director Sale
• Negative Sentiment: Broad insider selling reported in multiple SEC Form 4 filings (CEO, CFO, EVP, VP, CAO and others sold shares in early January). The scale and breadth of executive sales likely represent profit-taking or diversification and can create short-term downward pressure until offset by fresh operational news. Representative SEC filing: SEC Form 4
• Negative Sentiment: EVP Lee Scott Golden and other insiders sold modest-to-large blocks (multiple transactions disclosed), reinforcing the headline of concentrated insider exits. InsiderTrades Alert

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.